Pancragen and Sermorelin Interaction: Monitor | Peptide Database

Join others researching Telmisartan — share findings, ask questions, and learn from real experiences Telmisartan is an angiotensin II receptor blocker (ARB) originally developed for the treatment of hypertension and cardiovascular risk reduction. FDA-approved since 1998 and marketed as Micardis, it has become the preferred ARB among performance-enhancing drug users and anabolic steroid communities due to its long half-life, strong evidence for organ protection, and unique partial PPAR-gamma agonist activity. Unlike other ARBs, telmisartan activates peroxisome proliferator-activated receptor gamma (PPAR-gamma) at clinically relevant doses, conferring metabolic benefits that extend beyond blood pressure reduction. Anabolic androgenic steroids (AAS) are well-documented to elevate blood pressure, promote left ventricular hypertrophy, accelerate atherosclerosis, and impair renal function -- making proactive cardiovascular protection an essential component of harm reduction. Telmisartan addresses these concerns with once-daily dosing, 24-hour blood pressure coverage, and a favorable side effect profile that does not impair exercise performance or recovery. Telmisartan selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II from exerting its vasoconstrictive, aldosterone-secreting, and pro-fibrotic effects. By antagonizing AT1, telmisartan lowers systemic vascular resistance and blood pressure while simultaneously reducing pathological cardiac and vascular remodeling. This is particularly relevant for AAS users, where supraphysiological androgen levels stimulate the renin-angiotensin-aldosterone system (RAAS) and promote myocardial fibrosis and left ventricular hypertrophy. Telmisartan also has the longest half-life of any ARB (approximately 24 hours), providing consistent receptor blockade throughout the dosing interval. Its unique partial agonism of PPAR-gamma -- a nuclear receptor involved in glucose and lipid metabolism -- distinguishes it from other ARBs. PPAR-gamma activation enhances insulin sensitivity, improves adiponectin secretion, reduces visceral fat accumulation, and exerts anti-inflammatory effects. Additionally, telmisartan demonstrates nephroprotective properties by reducing intraglomerular pressure and proteinuria, and has been shown in the ONTARGET trial to provide cardiovascular protection comparable to the ACE inhibitor ramipril in high-risk patients.

First-line treatment for elevated LDL cholesterol and mixed dyslipidemia. Rosuvastatin 10-20 mg achieves LDL reductions of 45-55%, outperforming equivalent doses of other statins. Particularly appropriate when aggressive LDL lowering is required or when patients have not reached lipid targets on less potent statins. Widely used off-label to manage lipid disturbances caused by anabolic steroid cycles, especially oral AAS (oxandrolone, stanozolol, methandrostenolone) that severely impact lipid profiles. Typical on-cycle doses of 5-10 mg daily can meaningfully reduce LDL elevation, though HDL suppression caused by androgens is only partially mitigated. Most effective when started before or at the beginning of a cycle rather than reactively. Proven to reduce major cardiovascular events including myocardial infarction, stroke, and cardiovascular death. The JUPITER trial showed a 44% reduction in major cardiovascular events in apparently healthy individuals with elevated hsCRP. Particularly relevant for long-term AAS users who accumulate cardiovascular risk over time. Indicated for cardiovascular risk reduction in individuals without established cardiovascular disease but with risk factors such as dyslipidemia, family history, or elevated inflammatory markers. The JUPITER trial established benefit even in patients with LDL below 130 mg/dL if hsCRP was elevated above 2 mg/L. The METEOR trial demonstrated that rosuvastatin 40 mg significantly slowed progression of carotid intima-media thickness compared to placebo in low-risk patients with subclinical atherosclerosis. Suggests benefit in slowing vascular damage that may accumulate in chronic AAS users.